Company & Sponsor Intelligence

Wyeth is now a wholly owned subsidiary of Pfizer

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials10

Recruiting0

Completed9

Countries4

Therapeutic footprint

alzheimersdepression

Indexed studies

NCT00745576Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
alzheimers · FrancePHASE1

NCT00966966Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered
alzheimers · NetherlandsPHASE1

NCT00739037Study Evaluating PAZ-417 in Cerebrospinal Fluid in Subjects With Alzheimer's Disease
alzheimers · United StatesPHASE1

NCT00519298Study Evaluating Effects of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG in Healthy Subjects
alzheimers · FrancePHASE1

NCT00547560Study Evaluating Multiple Doses Of GSI-953 Within The Elderly Population
alzheimers · United StatesPHASE1

NCT00452504Single Ascending Dose Study of SRA-444 in Healthy Subjects
alzheimers · NetherlandsPHASE1

NCT00726115Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531
alzheimers · FrancePHASE1

NCT00445679Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD
depression · ChinaPHASE3

NCT00479297Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males
alzheimers · PHASE1

NCT00151333Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)
alzheimers · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →